NO921883L - Protein-c-inneholdende legemiddel - Google Patents

Protein-c-inneholdende legemiddel

Info

Publication number
NO921883L
NO921883L NO92921883A NO921883A NO921883L NO 921883 L NO921883 L NO 921883L NO 92921883 A NO92921883 A NO 92921883A NO 921883 A NO921883 A NO 921883A NO 921883 L NO921883 L NO 921883L
Authority
NO
Norway
Prior art keywords
protein
containing medicine
pharmaceutical composition
microcirculation
disturbances
Prior art date
Application number
NO92921883A
Other languages
English (en)
Other versions
NO304679B1 (no
NO921883D0 (no
Inventor
Johann Eibl
Ludwig Pichler
Hans Peter Schwarz
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of NO921883D0 publication Critical patent/NO921883D0/no
Publication of NO921883L publication Critical patent/NO921883L/no
Publication of NO304679B1 publication Critical patent/NO304679B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO921883A 1991-05-14 1992-05-13 Anvendelse av protein C eller aktivert protein C ved fremstilling av legemiddel NO304679B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0099191A AT397615B (de) 1991-05-14 1991-05-14 Arzneimittel enthaltend protein c

Publications (3)

Publication Number Publication Date
NO921883D0 NO921883D0 (no) 1992-05-13
NO921883L true NO921883L (no) 1992-11-16
NO304679B1 NO304679B1 (no) 1999-02-01

Family

ID=3504433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO921883A NO304679B1 (no) 1991-05-14 1992-05-13 Anvendelse av protein C eller aktivert protein C ved fremstilling av legemiddel

Country Status (10)

Country Link
US (1) US5549893A (no)
EP (1) EP0514367B1 (no)
JP (1) JP2945211B2 (no)
AT (2) AT397615B (no)
AU (1) AU658881B2 (no)
CA (1) CA2068630C (no)
DE (1) DE59206864D1 (no)
DK (1) DK0514367T3 (no)
ES (1) ES2093811T3 (no)
NO (1) NO304679B1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
DK0733371T3 (da) * 1995-03-21 2002-10-07 Baxter Ag Middel til subkutan administrering af protein C
US7100083B2 (en) * 2000-08-04 2006-08-29 Sun Microsystems, Inc. Checks for product knowledge management
US20030149677A1 (en) * 2000-08-04 2003-08-07 Bingham Paris E. Knowledge automation engine for product knowledge management
US7146536B2 (en) * 2000-08-04 2006-12-05 Sun Microsystems, Inc. Fact collection for product knowledge management
US7146535B2 (en) * 2000-08-04 2006-12-05 Sun Microsystems, Inc. Product knowledge management
US7051243B2 (en) * 2002-04-30 2006-05-23 Sun Microsystems, Inc. Rules-based configuration problem detection
AU2002302192B2 (en) 2001-06-13 2007-08-16 Zz Biotech Llc Treatment and composition for wound healing
JP5851246B2 (ja) * 2008-12-30 2016-02-03 リグスホスピタルＲｉｇｓｈｏｓｐｉｔａｌｅｔ 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
JP6273272B2 (ja) * 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
PL3137102T3 (pl) 2014-04-16 2022-02-07 Zz Biotech Llc Apc do stosowania w leczeniu nieprawidłowego bliznowacenia skóry

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
US4966764A (en) * 1989-02-24 1990-10-30 Olin Corporation Process for producing low aluminum membrane cell feedbrine
FR2658517B2 (fr) * 1989-04-12 1992-06-19 Fondation Nale Transfusion San Preparation de la proteine c activee et solution de proteine c activee ainsi obtenue.
AU6215290A (en) * 1989-09-05 1991-03-14 Eli Lilly And Company Method for activating protein c
EP0506821B1 (en) * 1989-12-29 1998-02-04 Zymogenetics, Inc. Hybrid protein c
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation

Also Published As

Publication number Publication date
NO304679B1 (no) 1999-02-01
AT397615B (de) 1994-05-25
DK0514367T3 (da) 1996-12-23
AU658881B2 (en) 1995-05-04
EP0514367A2 (de) 1992-11-19
DE59206864D1 (de) 1996-09-12
US5549893A (en) 1996-08-27
ATA99191A (de) 1993-10-15
ES2093811T3 (es) 1997-01-01
EP0514367B1 (de) 1996-08-07
EP0514367A3 (en) 1993-04-07
NO921883D0 (no) 1992-05-13
CA2068630A1 (en) 1992-11-15
CA2068630C (en) 2003-04-22
JP2945211B2 (ja) 1999-09-06
AU1615992A (en) 1992-11-19
ATE141057T1 (de) 1996-08-15
JPH05132427A (ja) 1993-05-28

Similar Documents

Publication Publication Date Title
MX9207630A (es) Composiciones farmceuticas de sabor enmascarado.
NO951592L (no) Fremgangsmåte for fremstilling av et transdermalt terapeutisk system
KR920019342A (ko) 골질환 치료제
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
NO921883D0 (no) Protein-c-inneholdende legemiddel
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
ES2067600T3 (es) Procedimiento para la fabricacion de preparados de inmunoglobulina, que contienen igm y/o iga, no modificados de administracion intravenosa.
GR3015765T3 (en) A novel thrombomodulin-like glycoprotein obtainable from urine.
DE69201660D1 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
DE69004532D1 (de) Topisch anzuwendende Defibrotid enthaltende Arzneizubereitungen.
DE68921908D1 (de) Zell-assoziierte Glucosyltransferase, Antikörper dagegen und eine diese enthaltende Zusammensetzung zur Prophylaxe von Karies.
ATE154507T1 (de) Dentalwerkstoffe auf basis von (meth)-acrylaten
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
SE9000207D0 (sv) Laekemedel samt anvaendningen av detsamma
TR199902335T2 (xx) Vask�ler bozukluklar�n tedavisi.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
ES2160927T3 (es) Composiciones farmaceuticas que comprenden interferon alfa humano natural.
DE3879837D1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
DK0495721T3 (da) Anvendelsen af et polypeptid med en humant-interleukin-2-aktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af pneumothorax
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
ES2127133B1 (es) Utilizacion de derivados 2,5-dihidroxibencenosulfonicos para la fabricacion de medicamentos destinados al tratamiento y a la prevencion de la enfermedad de alzheimer.
BG51386A1 (en) antitumour preparation
ITMI910442V0 (it) Struttura di zoccolo ortopedico, o simile, in particolare per la prevenzione o la cura del valgismo dell'alluce

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees